Recent Updates
Recently added Catalysts
MNPR Positive Sentiment

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Tuesday, September 5, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Monopar Therapeutics Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference. CEO Chandler D. Robinson is scheduled to begin the company’s webcast presentation on September 11, 2023, at 7:00 a.m. ET. The event includes opportunities for in-person one-on-one meetings from September 11 to 13, 2023, at Lotte New York Palace, NY. Monopar is focused on developing cancer treatments with a pipeline including drugs in various stages of clinical development.
Price reaction · baseline $3.185 (2023-09-01 close) · hit after-hours · clean, no other MNPR news in the window
day 0 close · peak
-0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Monopar is actively participating in a significant investment conference.
  • The presentation could enhance visibility and support for Monopar's innovative cancer treatments.
  • Opportunities for one-on-one meetings may foster investor interest and potential funding.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+140%
120-day peak, hindsight
Typical move
5.5%
average across 4 past catalysts
Cash runway
~97 mo
Minimal dilution risk
Lead asset
MNPR-101-PCTA-177Lu
Phase 1 · Solid Tumor, Adult

Full Press Release Details

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 11, 2023 at 7:00 a.m. ET. In person one-on-one meetings will take place at the Lotte New York Palace, NY, NY from September 11 - 13, 2023.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.
Monopar Therapeutics Inc.
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

Frequently Asked Questions

What event will Monopar Therapeutics present at?

Monopar Therapeutics will present at the H.C. Wainwright 25th Annual Global Investment Conference.

When is Monopar's presentation scheduled?

The presentation is scheduled for September 11, 2023, at 7:00 a.m. ET.

Where will the in-person meetings take place?

In-person one-on-one meetings will occur at the Lotte New York Palace, NY.

What is Monopar's main focus?

Monopar Therapeutics focuses on developing innovative treatments for cancer patients.

What are the key products in Monopar's pipeline?

Monopar's pipeline includes camsirubicin, MNPR-101, and MNPR-202 for cancer treatment.

ShareAdd on Google
Tags: MNPR Viatris Investor Conferences Healthcare Monopar Therapeutics H.C. Wainwright cancer treatments biopharmaceuticals
Last updated: Sep 5, 2023

Biotech snapshot

Cash runway
$105M liquidity · $1M/mo burn
~97 mo
Minimal dilution risk
Lead asset
MNPR-101-PCTA-177LuPhase 1
Solid Tumor, Adult →

Catalyst track record

+140%
best trade around MNPR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for MNPR.

See every catalyst's timing & PoA →